32 results on '"Müller, Cristina"'
Search Results
2. Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics
3. A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides
4. Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90
5. Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer
6. Combination of terbium-161 with somatostatin receptor antagonists—a potential paradigm shift for the treatment of neuroendocrine neoplasms
7. Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands
8. Promising potential of [177Lu]Lu-DOTA-folate to enhance tumor response to immunotherapy—a preclinical study using a syngeneic breast cancer model
9. Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates—new perspectives for folate receptor–targeted radionuclide therapy
10. Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC
11. Radiation dosimetry of 18F-AzaFol: A first in-human use of a folate receptor PET tracer
12. Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617
13. Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer
14. Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy
15. Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice
16. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
17. Production and separation of 43Sc for radiopharmaceutical purposes
18. 47Sc as useful β–-emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes
19. 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
20. 44Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations
21. Preclinical in vivo application of 152Tb-DOTANOC: a radiolanthanide for PET imaging
22. Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics
23. Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate
24. Increased physical activity severely induces osteoarthritic changes in knee joints with papain induced sulfate-glycosaminoglycan depleted cartilage
25. Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate
26. Improved PET Imaging of Tumors in Mice Using a Novel 18 F-Folate Conjugate with an Albumin-Binding Entity
27. PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues
28. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues
29. Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy
30. Preclinical evaluation of novel organometallic 99mTc-folate and 99mTc-pteroate radiotracers for folate receptor-positive tumour targeting
31. In vitro and in vivo targeting of different folate receptor-positive cancer cell lines with a novel 99mTc-radiofolate tracer
32. Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates—new perspectives for folate receptor–targeted radionuclide therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.